End-of-day quote
Shenzhen S.E.
23:00:00 09/05/2024 BST
|
5-day change
|
1st Jan Change
|
13.03
CNY
|
-0.46%
|
|
+2.60%
|
-8.30%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
4,679
|
4,116
|
4,104
|
4,198
|
4,145
|
3,801
|
-
|
Enterprise Value (EV)
1 |
4,679
|
4,116
|
4,104
|
4,198
|
4,145
|
3,801
|
3,801
|
P/E ratio
|
11.1
x
|
12.9
x
|
-
|
-
|
-
|
-
|
-
|
Yield
|
2.49%
|
-
|
2.63%
|
2.15%
|
1.83%
|
2.76%
|
2.92%
|
Capitalization / Revenue
|
0.21
x
|
-
|
0.16
x
|
0.16
x
|
0.14
x
|
0.13
x
|
0.12
x
|
EV / Revenue
|
0.21
x
|
-
|
0.16
x
|
0.16
x
|
0.14
x
|
0.13
x
|
0.12
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
1.37
x
|
-
|
1.06
x
|
1.03
x
|
0.98
x
|
0.92
x
|
0.91
x
|
Nbr of stocks (in thousands)
|
291,707
|
291,707
|
291,707
|
291,707
|
291,707
|
291,707
|
-
|
Reference price
2 |
16.04
|
14.11
|
14.07
|
14.39
|
14.21
|
13.03
|
13.03
|
Announcement Date
|
27/02/20
|
16/03/21
|
29/03/22
|
20/04/23
|
28/04/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
22,187
|
-
|
25,626
|
26,220
|
29,996
|
29,183
|
30,642
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
317.6
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
1.440
|
1.090
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.4000
|
-
|
0.3700
|
0.3100
|
0.2600
|
0.3600
|
0.3800
|
Announcement Date
|
27/02/20
|
16/03/21
|
29/03/22
|
20/04/23
|
28/04/24
|
-
|
-
|
Fiscal Period: December |
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
5,939
|
6,756
|
8,209
|
7,443
|
6,952
|
8,430
|
6,610
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
169.5
|
77.64
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
0.5800
|
0.2700
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/08/22
|
19/10/22
|
20/04/23
|
26/04/23
|
28/04/24
|
28/04/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
13.4%
|
-
|
11%
|
7.49%
|
6.03%
|
7.5%
|
8.4%
|
ROA (Net income/ Total Assets)
|
3.12%
|
-
|
4.19%
|
-
|
-
|
1.8%
|
1.9%
|
Assets
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
1 |
11.70
|
-
|
13.30
|
14.00
|
14.50
|
14.20
|
14.30
|
Cash Flow per Share
1 |
1.000
|
-
|
2.280
|
-0.5600
|
5.470
|
0.8900
|
1.090
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
27/02/20
|
16/03/21
|
29/03/22
|
20/04/23
|
28/04/24
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -8.30% | 526M | | +20.94% | 72.78B | | -1.26% | 24.24B | | +5.13% | 8.59B | | +8.25% | 8.38B | | -19.42% | 8.09B | | +5.56% | 4.81B | | +16.83% | 4.32B | | -1.83% | 4.05B | | -1.65% | 3.93B |
Pharmaceuticals Wholesale
|